Use of salusin ß for predicting atherosclerosis and components of the metabolic syndrome.

Salusin ß is a bioactive peptide, detectable in many tissues and body fluids, first identified nearly 20 years ago. Since then, many studies have been performed to define the role of salusin ß, concentrating on its role in atherosclerosis and conditions leading to vascular injury such as hypertension, diabetes and hyperlipidemia, in which salusin ß seems to play a proatherogenic role. Previous literature has evaluated salusin as a predictor of atherosclerosis. Herein, we performed online research using 5 databases, namely PubMed, Ovid, Web of Science, Scopus, and Cochrane Library. Inclusion criteria were articles published in the years 2017-2022, concerning the association between salusin ß and obesity, atherosclerosis, hypertension, and hyperglycemia. The aim of the review was to provide comprehensive data regarding the latest studies in this area. The latest research confirms that salusin ß plays an important role in the development of vascular remodeling, inflammation, hypertension, and atherosclerosis. Additionally, the peptide is associated with hyperglycemia and lipid disorders, and its widespread activity makes it a potential therapeutic target. However, there is a need for additional studies to confirm the potential role of salusin ß as a novel target for treatment. Many of the reports were performed in animal models, while research conducted in humans was generally based on small groups of patients and not always compared with healthy controls; studies enrolling children are rare.

Assessment of Metabolic Syndrome and Kidney and Heart Function in Childhood Cancer Survivors.

BACKGROUND: The survivors of childhood cancer suffer from a number of long-term side effects. These include atherosclerosis and cardiovascular diseases (CVDs) that develop earlier in adulthood than in the rest of the population. The aim of this study was to identify prognostic factors of developing atherosclerosis before the development of symptomatic CVD. METHODS: A total of 141 children that were 7-18 years old were examined; there were 116 survivors of childhood malignancies (hematopoietic and lymphoproliferative malignancies-52; neuroblastoma-22; Wilms tumor-24; other solid tumors-18) and 25 healthy controls. Anthropometric measurements, blood pressure measurements, ultrasonography of the abdomen, echocardiography, and laboratory tests were performed. RESULTS: There were no significant differences in gender distribution, time from the end of the treatment, weight, BMI, prevalence of central obesity, blood pressure and resistive index of the renal arteries, lipid profile, or glucose and fibrinogen levels. Patients with solid tumors had a significantly lower height and worse renal function. Patients with hematological malignancies significantly presented the lowest shortening fraction of the left ventricle. The salusin ß levels were significantly higher in the control group than among the patients. CONCLUSIONS: The type and severity of side effects are closely related to the type of neoplasm and the treatment that has been undergone. Careful observation and regular follow-up are necessary.